ArticleAnnals of surgical oncology2026
Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic significance of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) remains unclear. We aimed to evaluate its significance on surgical and long-term outcomes in a well-defined cohort of patients undergoing cytoreductive hepatectomy for small bowel NET liver metastasis (sbNETLM).
methodsPatients undergoing cytoreductive hepatectomy between January 2000 and December 2020 were included (CS, n = 154; non-functional, n = 133); post-progression analysis extended through December 2023 in 191 patients.Query
resultsAge (60 vs. 63 years; p = 0.059) and sex distribution (47% vs. 54% male; p = 0.278) were similar in patients with CS compared with non-functional sbNETLM. CS was associated with more (p < 0.001) and larger (p < 0.001) hepatic metastases, requiring more frequent major hepatectomies (p < 0.001). Postoperative morbidity (22% vs. 21%; p = 0.925) and 90 day mortality (1% vs. 2%; p = 0.666) were similar in major resections. In CS patients, median overall survival (mOS) and median progression-free survival (mPFS) were shorter (mOS: 10.1 vs. 12.5 years, p = 0.035; mPFS: 1.6 vs. 2.4 years, p = 0.015). In subgroups with extensive tumor burden, CS was linked to shorter mOS (9.2 vs. 15.3 years, p = 0.028). Post-progression, 50% of CS patients and 41% of initially non-functional sbNETLM developed secondary CS, increasing the risk of carcinoid heart disease and mortality from cardiac and renal failure. CS was the strongest liver metastasis-specific predictor of mortality in multivariable regression analysis (HR 1.73, p = 0.004).
conclusionWhile surgical risk is not elevated, long-term survival is reduced in CS. Secondary CS can develop after tumor progression, even in initially non-functional sbNETLM, further worsening prognosis. Regular screening and proactive management of CS may improve long-term outcomes.
Indexed as
Identifiers
41042466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.